TRIO-525

N/A

Report date: 2026/04/15 20:02:38

NME

Base Information

Drug NameTRIO-525

Drug Alias NameTRIO-525

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Trop-2Anti-Myeloid cell surface antigen CD33

TargetsTumor-associated calcium signal transducer 2Myeloid cell surface antigen CD33

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPurdue University University Of Washington

China Registration ClassN/A

Develop Information

Active CompaniesPurdue University University Of Washington

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A